The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.

The big pharma company will no longer progress emugrobart to late-stage trials in FSHD and SMA due to a lack of efficacy.

Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies for spinal muscular atrophy, Duchenne muscular dystrophy and Becker muscular ...

Chris Stoelhorst, Chairman of MARS Bioimaging, said: “With FDA clearance, we can now scale clinical adoption of our scanners in the United States, the world’s largest CT market. This milestone ...

Mirecule, Inc., a leader in Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, today announced an expansion of its strategic collaboration with Sanofi. This collaboration ...

Atamyo Therapeutics, a biotechnology company specializing in the development of next-generation gene therapies for limb-girdle muscular dystrophy (LGMD), announced at the MDA (Muscular Dystrophy ...

Parent Project Muscular Dystrophy (PPMD), in partnership with the Foundation to Eradicate Duchenne (FED), today ...

It's known as the 'Super Bowl of Bodybuilding' - a weekend where weightlifters gather in Columbus, Ohio to flex and put on display their hard work in achieving the 'perfect physique.' The Arnold ...

Novartis AG faces major patent expiries but is buying pipeline assets to sustain growth. Click for this NVS update.

Data from BridgeBio Pharma’s Phase 3 FORTIFY study show that BBP-418 significantly increases levels of a key disease biomarker that helps stabilize muscles in patients with limb-girdle muscular ...

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater ...

What is SMA? The rare genetic condition that Jesy Nelson’s twin daughters have - Former Little Mix star revealed her twin ...